How HIV Evades AZT

November 27, 1998

November 27, 1998-HHMI researchers have used x-ray crystallography to produce a three-dimensional picture of a key AIDS virus enzyme. The structure reveals details that clarify how HIV mutations render the retrovirus resistant to antiviral drugs such as AZT.

Once HIV invades a human cell, reverse transcriptase (RT), one of three enzymes used by HIV, reads the retrovirus's genetic material, RNA, and synthesizes DNA, which codes for viral proteins that commandeer the infected cell's protein-making machinery.

In an article published in the November 27, 1998, issue of the journal Science, Stephen C. Harrison, an HHMI investigator at Children's Hospital in Boston, and his colleagues from Harvard University, describe the active structure of RT. In order to capture RT in an active form, Harrison knew that the enzyme needed to be constrained, so he approached Harvard chemists, Gregory Verdine and his postdoctoral fellow Hulfgang Huang, and asked them to tether RT to DNA. The chemists modified both DNA and the RT protein so that the two would be attached by a permanent chemical bond.

"The really clever new trick that helped us trap a catalytically active complex was this modified chemistry," Harrison says. The first images of the structure of RT were produced in the early 1990s by HHMI investigator Thomas A. Steitz at Yale University. Steitz's research team used a catalytically-inactive form of the protein in their studies. Steitz and others showed that RT and other members of the DNA polymerase family of enzymes are composed of subunits that resemble fingers, a palm, and a thumb.

In the RT found in HIV, DNA lies across this hand, stretching from where the wrist would be toward the metaphorical pinkie. The structure shows that active RT looks like a slightly clenched hand, with the thumb almost touching the finger nearest to it. Most drugs that target RT mimic nucleotides. When the drugs are incorporated into DNA strands in the place of normal nucleotides, the strands stop growing, and this effectively stops viral replication. Mutations that confer resistance to AZT and other nucleotide analogs occur in the pocket between the thumb and forefinger where the nucleotide binds. The bending of the fingers that is clearly visible in the newly solved structure clarifies how mutations alter binding to the DNA nucleotide or to the nucleotide analog antiviral drugs such as AZT.

Harrison's group shows that these mutations prevent the nucleotide analog drugs from binding to the enzyme. These mutations do not prevent normal nucleotides from binding, however, which allows RT to continue making DNA for the virus.

"Because of very elegant chemistry accomplished by Verdine and Huang, we've been able to trap an informative complex that allows us to understand much better the resistance mutations," Harrison says. Harrison says he is also excited about the research because the structure of the catalytically-active form of RT may reveal general principles about how viral polymerases work.
-end-


Howard Hughes Medical Institute

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.